Table 2 Risk factor control and medication assessed at 3 and 12Â months of follow-up
From: Long-term outcome of vertebral artery origin stenosis in patients with acute ischemic stroke
| Â | Â | Baseline | 3-month follow-up | 12-month follow-up |
|---|---|---|---|---|
Asymptomatic VAO stenosis (n = 64) | Systolic BP (mmHg) | 151.0 ± 29.3 (n = 64) | 124.5 ± 15.4 (n = 51)* | 123.4 ± 13.8 (n = 42)* |
Diastolic BP (mmHg) | 84.6 ± 16.0 (n = 64) | 71.0 ± 10.1 (n = 51)* | 71.5 ± 8.8 (n = 42)* | |
Total cholesterol (mg/dl) | 171.8 ± 36.7 (n = 63) |  | 141.0 ± 34.7 (n = 49)* | |
LDL cholesterol (mg/dl) | 107.9 ± 29.7 (n = 59) |  | 80.7 ± 31.3 (n = 27)* | |
HDL cholesterol (mg/dl) | 43.3 ± 10.5 (n = 63) |  | 44.8 ± 11.7 (n = 48) | |
HbA1c (%)§ | 8.0 ± 2.2 (n = 30) |  | 7.0 ± 1.2 (n = 23)‡ | |
Number of evaluated patients | Â | 55 | 45 | |
 Antihypertensive drug (n,%) |  | 42 (76.4) | 37 (82.2) | |
 Antiplatelet agent or oral anticoagulant (n,%) |  | 53 (96.4) | 41 (91.1) | |
 Statin (n,%) |  | 36 (65.5) | 33 (73.3) | |
Symptomatic VAO stenosis (n = 73) | Systolic BP (mmHg) | 152.6 ± 22.6 (n = 73) | 123.3 ± 16.0 (n = 57)* | 125.6 ± 14.8 (n = 49)* |
Diastolic BP (mmHg) | 82.4 ± 15.3 (n = 73) | 69.9 ± 9.7 (n = 57)* | 72.8 ± 10.6 (n = 49)* | |
Total cholesterol (mg/dl) | 185.8 ± 37.3 (n = 73) |  | 148.0 ± 31.7 (n = 53)* | |
LDL cholesterol (mg/dl) | 112.0 ± 31.2 (n = 70) |  | 81.0 ± 27.5 (n = 30)* | |
HDL cholesterol (mg/dl) | 44.9 ± 10.6 (n = 73) |  | 47.1 ± 17.6 (n = 52) | |
HbA1c (%)§ | 8.3 ± 1.7 (n = 35) |  | 7.3 ± 0.9 (n = 22)†| |
Number of evaluated patients | Â | 59 | 51 | |
 Antihypertensive drug (n,%) |  | 39 (66.1) | 37 (72.5) | |
 Antiplatelet agent or oral anticoagulant (n,%) |  | 58 (98.3) | 49 (96.1) | |
 Statin (n,%) |  | 45 (76.3) | 39 (76.5) |